PATIENT PROFILES

Do you treat patients who could benefit from CARDAMYST™?

Meet Dani and Michael, 2 patients with PSVT*

*The following profiles are not of actual patients but are representative of possible patient experiences with PSVT.

Meet Dani.

NEWLY DIAGNOSED WITH PSVT

Dani

  • 40-year-old working mom of 2 young children

  • Frustrated by lengthy delay in her diagnosis

  • Exploring options to manage her PSVT without ablation

Medical History

  • Diagnosed 2 months ago

  • Episodes began 18 months ago and were misdiagnosed as panic attacks

  • No additional medical concerns or medications

PSVT Episode Assessment

  • 5 episodes over the last 18 months

  • Episodes varied in length, with several lasting nearly an hour

  • First and only emergency department (ED) visit for a PSVT episode was 2 months ago

  • Symptoms include rapid heart rate and shortness of breath

PSVT Management Considerations

  • Exploring options to manage her PSVT without ablation

  • Has been limiting activities with her children until she has an option to help manage her sudden episodes

Meet Michael.

LIVING WITH PSVT AND ON CHRONIC MEDICATION

Michael

  • 51-year-old trying to maintain his active lifestyle

  • Dissatisfied with chronic medication for episode prevention

  • Lives with uncertainty due to the unpredictability of episodes

Medical History

  • Diagnosed 4 years ago

  • Has hypertension

  • Taking metoprolol to help manage PSVT and hypertension

PSVT Episode Assessment

  • Experiences about 3 to 4 episodes a year

  • Episodes are usually short in duration, but occasionally they can be prolonged and severe

  • Last ED visit for a PSVT episode was 18 months ago

  • Symptoms may include rapid heart rate and anxiety

PSVT Management Considerations
  • Largely avoids going to ED because of the cost and prior negative experiences with IV adenosine

  • Previously declined ablation but willing to reconsider

  • Limits outdoor activities because of the uncertainty of his next episode

PSVT by the numbers

2.1M
estimated US prevalence1

~2x
as common in females than males1

~140K-526K
ED visits per year2

43 min
average episode length3†

PSVT symptoms vary, but may include palpitations/rapid heart, anxiety, difficulty breathing, and feeling hot, flushed, or sweaty are the most commonly reported3,4†

Based on a study of US and UK patients (N=247), where 3230 PSVT episodes were reported over 1 year.3

The unpredictable and heterogeneous nature of PSVT episodes may be life altering for patients4

Patients with PSVT report4:


  • Living with uncertainty
    Patients report living "on edge" from not knowing when an episode will occur, what will trigger it, and how long it may last.

  • Covering up symptoms
    When an episode occurs, it's common practice to conceal symptoms to appear normal and hope that they pass quickly.


  • Looking for triggers
    Patients seek to understand what factors might cause their episodes, and make changes to their diet and lifestyle to try to prevent future episodes.

  • Experimenting with management strategies
    Patients often test different techniques to shorten or end episodes when they occur.

Rapid conversion

Review clinical outcomes from the RAPID study.

Favorable safety profile

Most adverse events were localized to the nasopharynx.5,6

Connect with a rep

Get helpful information on CARDAMYST.

References:
1Rehorn M, Sacks NC, Emden MR, et al. Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. J Cardiovasc Electrophysiol. 2021;32(8):2199-2206. doi:10.1111/jce.15109 2Desai NR, Pollack CV Jr, Venkatesh AK, et al. Emergency department visits in the United States for paroxysmal supraventricular tachycardia are increasing among adults: an analysis from the nationwide emergency department sample. J Am Coll Emerg Physicians Open. 2016;7(2)1-10. doi:10.1016/j.acepjo.2026.100343 3Pokorney SD, Sears S, Wood K, Bharucha D, Granger B, Desai N. Characterising paroxysmal supraventricular tachycardia episodes by patient-perceived episode duration, symptoms and severity: longitudinal patient-reported outcomes. Poster presented at: European Heart Rhythm Association Annual Meeting; April 7-9, 2024; Berlin, Germany. 4Wood KA, Wiener CL, Kayser-Jones J. Supraventricular tachycardia and the struggle to be believed. Eur J Cardiovasc Nurs. 2007;6(4):293-302. doi:10.1016/j.ejcnurse.2007.02.006 5CARDAMYST (etripamil) Prescribing Information. Charlotte, NC: Milestone Pharmaceuticals USA, Inc. 6Stambler BS, Camm AJ, Alings M, et al; RAPID Investigators. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. Lancet. 2023;402(10396):118-128. doi:10.1016/S0140-6736(23)00776-6